Literature DB >> 24201068

Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease.

Olaf Schulz1, Alexander B Postnikov2, Tatiana I Smolyanova2, Alexey G Katrukha2, Ingolf Schimke3, Allan S Jaffe4.   

Abstract

OBJECTIVES: We have previously reported that increases in total pregnancy-associated plasma protein-A (PAPP-A) which are thought to be indicative of vulnerable plaques and thus poor outcomes predict outcomes in patients with stable coronary artery disease. We hypothesized that the determination of CT- and NT-fragments of insulin-like growth factor binding protein 4 (CT- and NT-IGFBP4) which should be indicative of free PAPP-A would result in better performance.
METHODS: In 229 stable cardiovascular patients with indication for heart catheterization after performance of a stress test and an echocardiogram, CT- and NT-IGFBP4 were measured. Their values were investigated in relation to clinical characteristics, findings of noninvasive investigations, laboratory data and coronary angiography as well as to outcomes after a follow-up of 1094±307days.
RESULTS: CT-IGFBP4 values were independently predicted by patients with B-type (p=0.0069) or complex coronary lesions (p=0.0445). B-type and vulnerable coronary lesions were independently predicted by levels of CT-IGFBP4≥a cutoff of 31.55ng/mL derived from ROC analysis (p=0.0090 and 0.0480). NT-IGFBP4 was not predictive of coronary characteristics. Both IGFBP4 fragments were strongly dependent on age and renal function and were not predictive of outcomes.
CONCLUSION: Despite the relation of CT-IGFBP4 to a more severe coronary artery disease, CT- and NT-IGFBP4, in contrast to our report based on total PAPP-A, failed to predict any long-term outcomes in patients with stable cardiovascular disease. Further knowledge about the interaction of the PAPP-A-insulin-like growth factor system is needed to explain values of IGFBP4 fragments in these patients.
© 2013.

Entities:  

Keywords:  IGF fragments; PAPP-A

Mesh:

Substances:

Year:  2013        PMID: 24201068     DOI: 10.1016/j.clinbiochem.2013.10.027

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  5 in total

1.  Insulin-Like Growth Factor Binding Protein 4 Fragments Provide Incremental Prognostic Information on Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction.

Authors:  Rikke Hjortebjerg; Søren Lindberg; Sune Pedersen; Rasmus Mogelvang; Jan S Jensen; Claus Oxvig; Jan Frystyk; Mette Bjerre
Journal:  J Am Heart Assoc       Date:  2017-03-17       Impact factor: 5.501

Review 2.  Current IGFBP-Related Biomarker Research in Cardiovascular Disease-We Need More Structural and Functional Information in Clinical Studies.

Authors:  Andreas Hoeflich; Robert David; Rikke Hjortebjerg
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-16       Impact factor: 5.555

Review 3.  CT-IGFBP-4 as a Predictive Novel Biomarker of Ischemic Cardiovascular Events and Mortality: A Systematic Review.

Authors:  Abhinav Bhattarai; Pritam Singh Sunar; Sangam Shah; Rajan Chamlagain; Nishan Babu Pokhrel; Pitambar Khanal; Sanjit Kumar Sah; Sujan Poudel; Kapil Belbase; Swati Chand; Rajaram Khanal; Anil Bhattarai
Journal:  J Interv Cardiol       Date:  2022-08-21       Impact factor: 1.776

4.  Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction.

Authors:  Germán Cediel; Ferran Rueda; Claus Oxvig; Teresa Oliveras; Carlos Labata; Oriol de Diego; Marc Ferrer; M Cruz Aranda-Nevado; Judith Serra-Gregori; Julio Núñez; Cosme García; Antoni Bayes-Genis
Journal:  Cardiovasc Diabetol       Date:  2018-04-30       Impact factor: 9.951

5.  CT-IGFBP-4 as a novel prognostic biomarker in acute heart failure.

Authors:  Alexey A Konev; Alexey V Kharitonov; Fedor N Rozov; Evgeny P Altshuler; Daria V Serebryanaya; Johan Lassus; Veli-Pekka Harjola; Alexey G Katrukha; Alexander B Postnikov
Journal:  ESC Heart Fail       Date:  2020-01-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.